Diabetes Drugs Market size is estimated to grow at a valuation of USD 166.8 Billion by 2035; Rising Prevalence of Diabetes is Expected to Pitch the Market Expansion

Download Sample

Published Date: May 2025

Diabetes drugs, are prescription medications used to regulate blood glucose levels in diabetics. The diabetes drugs market growth is being driven due to rising global prevalence, aging population, increased awareness, and advancements in treatments. The market diversifies with increased focus on personalized, accessible treatments, exploring new mechanisms like nanotechnology, AI, and targeted therapies to address complications and improve long-term health outcomes.

Segmentation Analysis:

By Diabetes Type	Type 1 and Type 2
By Drug Class	Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others
By Route of Administration	Oral, Subcutaneous, and Intravenous
By Distribution Channel	Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others

Report Highlights:

Diabetes drugs market size is accounted at USD 88.7 Billion in 2025.
Target market size is expected to develop at a rate of USD 166.8 Billion by 2035 and at a CAGR of 7.2%.
Stemming from diabetes type, the type 2 diabetes segment is expected to rule over the diabetes drugs market share.
Dependent upon drug class, the GLP-1 receptor agonists is holding the upper hand in the diabetes drugs market.
Based on route of administration, the oral route of administration is dominating the diabetes drugs market.
Stemming from distribution channel, the retail pharmacies segment is governing the diabetes drugs market.
Geographically, North America is leading the diabetes drugs market share.
Europe is the region which has the fastest growing diabetes drugs market, during the forecast period.

Market Dynamics:

Growing Factor	Challenge Factor	Market Trend
The Rising Aging Population	Side Effects Of Diabetes Drugs	Amalgamating Advanced Technologies With Diabetes Drugs

Key Highlights:

In March 2025, Pharmaceutical company, Morepen Laboratories Ltd had launched a new treatment for Type 2 diabetes, heart failure, and chronic kidney disease. The drug, Empamore, was said to provide an affordable and high-quality alternative to existing treatments for millions of patients. Empamore contained empagliflozin and was available in multiple formulations, including 10mg and 25mg doses, as well as combination variants with metformin (500mg/1000mg).

Report Analysis:

Factors Stimulating Insulin Secretion:

Glucose.
Amino acids (leucine, arginine).
Hormones such as glucagon-like polypeptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, high concentrations of fatty acids, and β-adrenergic sympathetic activity.
Stimulatory drugs are sulfonylureas, meglitinide and nateglinide, isoproterenol, and acetylcholine.

Browse ∼40 market data tables and ∼35 figures through ∼170 slides and in-depth TOC on “Diabetes Drugs Market, By Diabetes Type (Type 1 and Type 2), Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others), Route of Administration (Oral, Subcutaneous, and Intravenous), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Others), and By Region - Trends, Analysis, and Forecast till 2035”

Segmentation:

By Diabetes Type:

Type 1
Type 2

By Drug Class:

Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others

By Route of Administration:

Oral
Subcutaneous
Intravenous

By Distribution Channel:

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Others

By Region:

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- Indonesia
- Malaysia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa

For more insights into the Diabetes Drugs Market and its future trends, visit link below: https://www.prophecymarketinsights.com/market_insight/Global-Diabetes-Drugs-Market-4553

Competitive Landscape of Diabetes Drugs Market:

The prominent players operating in the market include, Sanofi, Novo Nordisk A/S, Lilly, DAIICHI SANKYO COMPANY, LIMITED, AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Johnson & Johnson Services, Inc., Akros Pharma Inc., Adocia, Biocon, and Pfizer Inc.